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ABSTRACT
Pro-inflammatory mediators such as TNF-α induce caspase activation in
endothelial cells, which leads to degradation of cellular proteins, induction of apoptotic
signaling, and endothelial cell dysfunction. New therapeutic agents that can inhibit
caspase activation may provide protection against inflammatory injury to endothelial
cells. In the present study, we examined the effects of selective histone deacetylase
6 (HDAC6) inhibition on TNF-α induced caspase 3 activation and cell-cell junction
dysfunction in lung endothelial cells. We also assessed the protective effects of HDAC6
inhibition against lung inflammatory injury in a mouse model of endotoxemia. We
demonstrated that selective HDAC6 inhibition or knockdown of HDAC6 expression
was able to prevent caspase 3 activation in lung endothelial cells and maintain lung
endothelial cell-cell junctions. Mice pre-treated with HDAC6 inhibitors exhibited
decreased endotoxin-induced caspase 3 activation and reduced lung vascular injury
as indicated by the retention of cell-cell junction protein VE-Cadherin level and
alleviated lung edema. Collectively, our data suggest that HDAC6 inhibition is a potent
therapeutic strategy against inflammatory injury to endothelial cells.

INTRODUCTION

barrier integrity requires interactions of intercellular
junctions, actin cytoskeleton and microtubules [5].
Adherens junctions (AJs) and tight junctions play
essential roles in supporting endothelial barrier function
[2–4]. ZO-1 and VE-cadherin are main components of TJs
and AJs respectively. TNF-α induces endothelial barrier
disruption by dis-organization of microtubule, actin
cytoskeleton and cell junctions [6–9].
HDAC6, a member of class II histone deacetylase
(HDACs) [10–12], is localized in the cytoplasm and
the nucleus [10–12]. HDAC6 inhibition possesses antitumor and anti-inflammation effects [13–15]. HDAC6 has
many endogenous substrates including chaperones and
cytoskeletal proteins [16]. Stabilization of cytoskeletal
proteins and modulation of chaperones by HDAC6
may protect against endothelial cell injury [16, 17].
Indeed, HDAC6 deletion renders mice less vulnerable to
endotoxin-induced inflammatory injury [18]. However, the
effects of HDAC6 inhibition on caspase 3 activation and
endothelial cell function remain to be determined.

Inflammation-mediated endothelial cell damage
including inflammatory lung vascular injury is often
associated with caspase activation and endothelial
cell barrier dysfunction [1]. Over-production of proinflammatory mediators such as tumor necrosis factor
(TNF)-α is a major cause of endothelial cell injury during
inflammation [1]. Tumor necrosis factor (TNF)-α-induced
caspase activation and endothelial cell dysfunction
contribute to inflammatory vascular injury in endotoxemia
and sepsis [1]. New agents that can prevent inflammatory
injury to endothelial cells could provide therapeutic benefits.
Activated caspases are known to induce apoptosis
by cleaving endogenous substrates and alter other cellular
functions including cell-cell junctions [2–4]. Caspase-3
activation plays an important role in endothelial cell
barrier dysfunction as a result of apoptotic signaling and
re-organization of cell-cell junction proteins including
ZO-1 and VE-Cadherin [2–4]. Maintaining of endothelial
www.impactjournals.com/oncotarget

54714

Oncotarget

Tubastatin A and CAY10603 are potent and highly
selective HDAC6 inhibitors with IC50 of 15 nM and 2 pM
in a cell-free assay, respectively [19]. Tubastatin A has been
reported to possess anti-inflammatory effects [20–23].
Tubastatin A treatment can prevent stress responses and
prolong survival during systemic inflammation [24–28].
In the present study, we investigated the effects of
HDAC6 knockdown and HDAC6 inhibitors Tubastatin A
and CAY10603 on TNF-α-induced caspase 3 activation
in endothelial cells in vitro. We examined the effects of
Tubastatin A and CAY10603 on cell-cell junction integrity
and endothelial permeability in primary human lung
endothelial cells. Furthermore, the effects of Tubastatin A
and CAY10603 on caspase 3 activation and lung edema
formation in vivo was assessed in a mouse model of
endotoxemia.

barrier dysfunction [29, 30]. We first assessed whether
HDAC6 inhibition can block caspase-3 activation in lung
endothelial cells. HPAECs and HLMVECs were pretreated with Tubstatin A, then challenged with TNF-α. Our
results showed that Tubstatin A potently blocked TNF-αinduced caspase-3 activation (cleaved caspase-3 level) in
endothelial cells (Figure 1).

HDAC6 knockdown and CAY10603 treatment
attenuate TNF-α-induced caspase-3 activation in
endothelial cells
To confirm the specific effects of HDAC6 inhibition
on TNF-α-induced caspase-3 activation, we used HDAC6
siRNA knockdown and another selective HDAC6 inhibitor
CAY10603 in our study. HPAECs were challenged with
TNF-α after siRNA knockdown or CAY10603 treatment.
HDAC6 knockdown and CAY10603 treatment both
inhibited TNF-α-induced caspase-3 activation (Figure 2).

RESULTS
Tubstatin a inhibits TNFα-induced caspase-3
activation in lung endothelial cells

HDAC6 inhibition alleviates TNF-α-induced
disruption of tight junctions in endothelial cells

TNF-α is a major pro-inflammatory mediator
known to induce endothelial injury during inflammation
(17, 21, 27). TNF-α induces caspase 3 activation which
leads to subsequent cellular damage including endothelial

Caspase-3 activation is associated with endothelial
cell-cell junction disruption [2–4]. We next conduct
experiments to assess whether HDAC6 inhibition could

Figure 1: HDAC6 inhibition by Tubastatin A attenuates caspase-3 activation in endothelial cells. HPAECs and HLMVECs

were pre-treated with Tubastatin A (TubA, 3 µM) for 6 h, then challenged with TNF-α (20 ng/ml) for 18 h. Cells were divided into 4 groups:
Control (Con), TNF-α alone (TNFα), Tubastatin A alone (TubA), and TNF-α+Tubastatin A (TNFα+TubA). Representative blots and
densitometry analysis of cleaved-caspase-3 in HPAECs (A) and HLMVECs (B). *P < 0.05 versus TNF-α group, n = 3.
www.impactjournals.com/oncotarget
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prevent TNF-α-induced damage to endothelial cellcell junctions. We observed endothelial cells ZO-1
disassembly at tight junctions after TNF-α challenged by
immunofluorescence assay. Pre-treatment with Tubstatin
A prevented the disruption in HPAECs and HLMVECs
(Figure 3).

down-regulation of VE-Cadherin was also blocked by
CAY10603 and Tubastatin A pre-treatment (Figure 5).

HDAC6 inhibition blocks endotoxin-induced
caspase-3 activation and VE-Cadherin downregulation in the lung

TNF-α is a major pro-inflammatory mediator known
to induce trans-endothelial hyper-permeability during
inflammation [1, 7, 9]. We examined the effects of HDAC6
inhibition by CAY10603 on TNF-α-induced endothelial
permeability. TNF-α challenge caused increased
endothelial permeability to FITC-dextran in HPAECs.
Cells pre-treated with CAY10603 exhibited significant
reduction of TNF-α-induced endothelial permeability to
FITC-dextran (Figure 6A). We also examined the effects
of CAY10603 on lung vascular permeability in the mouse
model of endotoxemia. In our studies, endotoxin-induced
lung edema formation was significantly inhibited by
CAY10603 pre-treatment (Figure 6B).

HDAC6 inhibition reduces TNF-α-induced
endothelial permeability and attenuates lung
edema formation in endotoxemia

To assess the therapeutic potential of HDAC6
inhibition against endothelial cell injury during acute
inflammation, we examined the effects of CAY10603 on
caspase-3 activation in a mouse model of endotoxemia.
In our studies, endotoxin-induced caspase-3 activation in
the lung tissues was significantly inhibited by CAY10603
and Tubastatin A pre-treatment. (Figure 4). Furthermore,
endotoxin challenge caused down-regulation of adherens
junction protein VE-Cadherin in the lung tissues. The

Figure 2: HDAC6 knockdown and HDAC6 inhibition by CAY10603 block TNF-α-induced caspase-3 activation in
endothelial cells. (A) HPAECs were transfected with HDAC6 siRNA or control siRNA for 48 h, then challenged with TNF-α (20 ng/ml)
for 24 h. Cells were divided into 4 groups: Control (Con), TNF-α alone (TNFα), siRNA alone (siRNA), and TNF-α+siRNA(TNFα+siRNA).
(B) HPAECs were pre-treated with CAY10603 (CAY, 0.1 µM) for 6 h, then challenged with TNFα (20 ng/ml) for 18 h. Cells were divided
into 4 groups: Control (Con), TNF-α alone (TNFα), CAY10603 alone (CAY), and TNF-α+CAY10603 (TNFα+CAY). Representative blots
and densitometry analysis of cleaved caspase-3. *P < 0.05 versus TNF-α group, n = 3.
www.impactjournals.com/oncotarget
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Figure 3: HDAC6 inhibition prevents TNF-α-induced ZO-1 disassembly in endothelial cells. HPAECs and HLMVECs were
pre-treated with Tubastatin A (TubA, 3 µM) for 6 h, then challenged with TNF-α (20 ng/ml) for 18 h. Cells were divided into 4 groups:
Control (Con), TNF-α alone (TNFα), Tubastatin A alone (TubA), and TNF-α+Tubastatin A (TNFα+TubA). Immunofluorescence staining
of ZO-1 in HPAECs (A) and HLMVECs (B). Images are representatives of three to six independent experiments.

Figure 4: HDAC6 inhibition reduced LPS-induced lung caspase-3 activation in endotoxemia. (A) C57BL/6 mice were

divided into four groups: Control (Con, n = 6); LPS (LPS, n = 7), CAY10603 (CAY, n = 6); CAY10603+LPS (CAY+LPS, n = 7). Mice
were pre-treated with CAY10603 for 2 h, then challenged with LPS for 24 h. Lung tissue were collected. (B) C57/B6 mice were divided
into three groups: Control (Con, n = 6); LPS (n = 7); Tubastatin A (TubA) + LPS (n = 6). Mice were pre-treated with Tubastatin A for 6 h,
then challenged with LPS. 24 h after LPS challenge, lung tissues were collected. Representative blots and densitometry analysis of cleaved
caspase-3 in lung tissues. *P < 0.05 versus LPS group.
www.impactjournals.com/oncotarget
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Figure 5: HDAC6 inhibition prevents LPS-induced VE-cadherin down-regulation in lung tissues. (A) C57BL/6 mice were

divided into four groups: Control (Con, n = 6); LPS (LPS, n = 7), CAY10603 (CAY, n = 6); CAY10603+LPS (CAY+LPS, n = 7). Mice were
challenged by CAY10603 for 2 h, then challenged with LPS for 24 h. Lung tissue were collected. (B) C57BL/6 mice were divided into three
groups: Control (Con, n = 6); LPS (n = 7); Tubastatin A (TubA)+LPS (n = 6). Mice were challenged by LPS with or without Tubastatin A
(TubA) pre-treatment. 24 h after LPS challenge, lung tissues were collected. Representative blots and densitometry analysis of VE-cadherin
level in lung tissues. *P < 0.05 versus LPS group.

Figure 6: HDAC6 inhibition alleviates TNF-α-induced endothelial hyper-permeability and lung edema in endotoxemia.

(A) HPAECs were pre-treated with CAY10603 (CAY, 0.1 µM) for 6 h, then challenged with TNFα (20 ng/ml) for 18 h. Cells were divided
into 4 groups: Control (Con), TNF-α alone (TNFα), CAY10603 alone (CAY), and TNF-α+CAY10603 (TNFα+CAY). TNF-α-induced
endothelial permeability to FITC-Dextran was measured (n = 4). *P < 0.05 versus TNF-α group. (B) C57BL/6 mice were divided into four
groups: Control (Con, n = 6); LPS (LPS, n = 7), CAY10603 (CAY, n = 6); CAY10603+LPS (CAY+LPS, n = 7). Mice were pre-treated with
CAY10603 for 2 h, then challenged with LPS for 24 h. Lung Wet/Dry weight ratio was measured. *P < 0.05 versus LPS group.
www.impactjournals.com/oncotarget
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DISCUSSION

Cadherin expression is critical in supporting lung vascular
barrier integrity [43]. We demonstrated that Tubastatin A
and CAY10603 were able to prevent the reduction of VECadherin in lung tissues after LPS challenge. Our results
suggest that HDAC6 inhibition is a new approach that can
modulate endothelial cell junction stability in inflammatory
lung injury. More studies are needed in the future to further
investigate this new pathway.
In summary, selective HDAC6 inhibition by
CAY10603 and Tubastatin A prevents TNF-α-induced
endothelial cell dysfunction. HDAC6 inhibitors prevent
caspase-3 activation in endothelial cells and inhibit TNFα-induced endothelial barrier dysfunction by maintaining
cell-cell junction integrity. HDAC6 inhibitors prevented
endotoxin-induced lung caspase-3 activation and lung
edema, suggesting that selective HDAC6 inhibition
possesses therapeutic potential to treat endothelial cell
dysfunction during acute inflammation.

TNF-α is a potent pro-inflammatory mediator known
to cause endothelial cell apoptosis and endothelial barrier
disruption [7, 9, 31–33]. TNF-α plays an important role
in many inflammatory diseases including lung vascular
injury [1]. Activation of caspases including caspase 3
contributes to TNF-α induces endothelial cell dysfunction
such as hyper-permeability [2–4]. Caspase activation
mediates apoptotic signaling and disruption of cell
junction complex [2–4], contributing to TNF-α-induced
breakdown of endothelial barrier function [2–4]. Similar
effects were observed in our in vitro studies in primary
human lung endothelial cells. Therefore, new agents that
can inhibit TNF-α-induced caspase activation and preserve
endothelial cell junctions could serve as therapeutic agents
against TNF-α-induced endothelial cell dysfunction.
HDAC6 inhibition has been reported to prolong
survival in murine models of systemic inflammation and
injury [20, 24, 25]. However, mechanisms underlying the
protective effects observed by HDAC6 inhibition remain
to be determined. In the present study, we demonstrated
that HDAC6 inhibition potently inhibited TNF-α-induced
caspase 3 activation and endothelial barrier dysfunction,
suggesting that HDAC6 inhibition could provide protection
against inflammation-mediated endothelial cell injury.
Caspase activation mediates apoptosis and redistribution of proteins that are known to modulate
endothelial barrier function including ZO-1 and VECadherin [2–4]. Protein acetylation can modulate caspase
activation [2]. In our studies, HDAC6 inhibition by
HDAC6 inhibitors or siRNA knockdown resulted in
reduced caspase 3 activation. It has been reported that
microtubule disruption leads to increased apoptotic
signaling and caspase activation [34, 35]. α-tubulin is
a endogenous substrate of HDAC6 [10, 11, 36–38].
Acetylation of α-tubulin at Lys40 stabilizes microtubule
structures [12, 38–41]. The decreased caspase 3 activation
by HDAC6 inhibition could be due to its protection
against microtubule disassembly by α-tubulin acetylation.
HDAC6 has been reported to modulate the function of
chaperones such as Hsp90 [17]. Inhibition of HDAC6
down-regulates Hsp90-dependent RhoA activity and
signaling, which then suppresses actin cytoskeleton reorganization and cell contraction [17]. HDAC6 has also
been reported to modulate the function of Survivin, an
anti-apoptotic protein [42]. Survivin inhibits apoptotic
signaling by inactivating caspases [42]. Our data suggest
that inhibition of caspase-3 activation by HDAC6
inhibition provides potent protection against TNF-αinduced endothelial cell dysfunction.
We also showed that HDAC6 inhibition effectively
suppress caspase-3 activation and maintain lung endothelial
barrier integrity in vivo. HDAC6 inhibitors prevented
caspase 3 activation in lung tissues with reduced lung
edema in a mouse model of endotoxemia. Maintaining VEwww.impactjournals.com/oncotarget

MATERIALS AND METHODS
Reagents
β-actin, ZO-1, caspase-3 antibodies were
purchased from Cell Signaling Technology (Danvers,
Massachusetts). VE-cadherin antibody was obtained from
Santa Cruz Biotechnology (Dallas, Texas). Recombinant
Human TNF-α was from R&D Systems (Minneapolis,
Minnesota). Tubastatin A, CAY10603 were obtained from
Selleck Chemicals (Houston, Teaxs). Lipopolysaccharide
(LPS) from Escherichia coli 0111:B4 was purchased from
Sigma Aldrich (St. Louis, Missouri). Endothelial growth
medium (EBM-2) was obtained from Lonza (Allendale,
NJ). In Vitro Vascular Permeability Assay (96-Well)
kit was purchased from EMD Millipore (Billerica,
Massachusetts). Lipofectamine RNAiMAX reagent,
HDAC6 siRNA and control siRNA were obtained from
Life technologies (Carlsbad, California).

Cell culture
Human pulmonary arterial endothelial cells
(HPAECs) and human lung microvascular endothelial
cells (HLMVECs) were purchased from Lonza (Allendale,
NJ). Cells were grown in EGM-2 supplemented with fetal
bovine serum (FBS) and cultured in an incubator at 37°C
in 5% CO2 and 95% air. Cells from passages 5 to 9 were
used in the experiments.

HDAC6 siRNA knockdown
HDAC6 siRNA knockdown was conducted as
described previously [41]. Cells were transfected with
siRNAs for 48 h according to the manufacture’s protocol.
siRNA-transfected cells were then stimulated with 20 ng/ml
TNF-α for 24 h.
54719
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Immunofluorescence and immunoblotting assays
For immunofluorescence assay, cells were grown
on glass coverslips pre-coated with 0.1% gelation. After
the treatment, cells were fixed in –20°C methanol and
washed with PBS on ice. Cells were blocked with 1%
BSA in PBS, then incubated with primary antibody. After
3 washes with TBS, cells were incubated with Alexa Fluor
594 secondary antibody. The coverslips were mounted
on the slides with DAPI. Immunoblotting assays of cell
and lung tissue samples were conducted as described
previously [43, 44].

All the authors declared no competing interests.
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